Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales

VELDONA® Pet will hit shelves in Taiwan in June, with launches in other regions to follow

Multiple new VELDONA® Pet products set to launch as Ainos enters the growing global pet care market

SAN DIEGO, CA / ACCESSWIRE / May 30, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has launched its VELDONA® Pet cytoprotein health supplements. VELDONA® Pet will first be marketed in Taiwan in June, with near-term plans to expand sales and marketing in other markets. Multiple new VELDONA® Pet products are in the works. Ainos targets approximately US$20 million in revenues from VELDONA® Pet during 2024, boosted by its growing product portfolio and expansion into new markets.

Chun-Hsien Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, "The second half of 2023 will be a very exciting period for Ainos. In addition to Taiwan, we are actively working to develop greater market opportunities for VELDONA® Pet in Asia and the United States. There is a huge addressable market for our product: China has around 117 million pet dogs and cats, Japan has approximately 18 million, and the U.S. has 190 million. We expect that VELDONA® Pet products will position us to capture the lucrative global pet care market, which is projected to grow to over US$325 billion in 2028 from US$223 billion in 2021, according to Fortune Business Insights."

"We are developing multiple new products based on VELDONA® Pet to provide pet owners with more innovative options to support their pets' health," Mr. Tsai said. "Boosted by our growing product portfolio and expansion into new markets, our ambition is that VELDONA® Pet will generate approximately US$20 million in revenues during 2024."

"The introduction of Ainos' VELDONA® Pet health supplements in Taiwan marks the beginning of a new chapter in our company's story," Mr. Tsai added. "We leveraged 40 years of interferon research to develop VELDONA® Pet, which now serves as a vital component of our next stage of growth. The fact that we were able to bring it to market a quarter ahead of schedule is yet another testament to our team's unparalleled expertise and ability to execute."

"We expect VELDONA® Pet to be available for sale in Taiwan in June. With approximately one in four Taiwanese families now owning pets, Taiwan is the ideal location for our product launch. There are currently around three million pet dogs and cats in Taiwan, surpassing the number of children under 14 years old, and this number is projected to grow to four million by 2025. Recognizing the significant market opportunity, the U.S. Department of Agriculture Foreign Agricultural Service recently highlighted Taiwan as one of the four countries with the ‘best prospects' for U.S. pet food exporters," Mr. Tsai said.

About VELDONA® Pet

Based on Ainos' low-dose oral interferon-alpha ("IFNα") formulation, VELDONA® Pet supplements are backed by numerous research studies and clinical trials, and are manufactured with world-class materials in a highly certified food-grade plant. VELDONA® maintains immunity and contributes to gum and skin health, relieving allergies and reducing stress in cats and dogs. Interferon is naturally produced by an organism's body. When cells are invaded by foreign particles, immune signaling molecules notify neighboring cells. Once neighboring cells receive the interferon's protein signal through their surface receptors, they initiate and modulate the immune system to protect felines and canines from gum and skin diseases, allergies, and stress-related conditions.

A clinical study, sponsored by Ainos and conducted by the state-of-the-art Agricultural Technology Research Institute, has demonstrated that VELDONA® helps maintain the immune systems of cats and dogs. Numerous studies have reported the benefits of interferons in maintaining gum health and skin health, relieving discomfort caused by allergies, and soothing emotional stress in cats and dogs. VELDONA® Pet not only provides protection against common and hard-to-diagnose diseases including feline chronic gingivostomatitis (FCGS), a severe oral mucosal inflammatory disease afflicting cats, and canine atopic dermatitis (CAD), an inflammatory skin disease found in dogs, but also offers the safest and highest quality products on the market.

About Ainos, Inc.

Headquartered in San Diego, California, Ainos, Inc. is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. Powered by its AI Nose platform, the lead POCT candidate, Ainos Flora, is a telehealth-friendly POCT for women's health and certain common STIs. To learn more, visit https://www.ainos.com.

Follow Ainos on Twitter (@AinosInc) and LinkedIn to stay up-to-date.

Forward-Looking Statements

This press release contains "forward-looking statements" about Ainos within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.

Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the planned drug treatments announced in this press release; the Company's dependence on revenues from the sale of COVID-19 test kits; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; and the Company's success in managing the growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' most recent Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission, many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's Form 10-K, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.

The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.

Investor Relations Contact

ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: Ainos.IR@icrinc.com

SOURCE: Ainos, Inc.